Has David Diaz, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,302 in general payments to David Diaz, MD across 23 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Diaz, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Diaz, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Diaz, MD

Psychiatry · Indianapolis, INNPI 1932101391

Payments from drug & device makers

$2,302in general payments, 2019–2025

Across 23 payments — averaging $100.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$588
Alkermes, Inc.$319
Sunovion Pharmaceuticals Inc.$254
Teva Pharmaceuticals USA, Inc.$246
Neurocrine Biosciences, Inc.$227
AbbVie$213
plus $454 from 5 others

What the payments were for

Food & beverage$2,302100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	5	$588
Alkermes, Inc.	3	$319
Sunovion Pharmaceuticals Inc.	4	$254
Teva Pharmaceuticals USA, Inc.	2	$246
Neurocrine Biosciences, Inc.	2	$227
AbbVie(2 entities)	2	$213
Axsome Therapeutics, Inc.	1	$125
E.r. Squibb & Sons, L.L.C.	1	$121
Otsuka America Pharmaceutical, Inc.	1	$115
Bioxcel Therapeutics, Inc.	1	$78
Supernus Pharmaceuticals, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,302 in reported general payments places this provider in the 75th percentile of 514 psychiatry providers in Indiana.

See all psychiatry providers in Indiana →

Medicare billing

Part B allowed, 2024

$8,767

Medicare patients

Services billed

108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other psychiatry in Indianapolis

Anantha ShekharIndianapolis$433K
Leslie HulvershornIndianapolis$159K
Charles BeasleyIndianapolis$129K
Alan BreierIndianapolis$114K
John NurnbergerIndianapolis$104K
Susan ConroyIndianapolis$73K
Dmitry ArbuckIndianapolis$40K
Michael FrancisIndianapolis$26K
Albert AllenIndianapolis$24K
Jerad DaltonIndianapolis$20K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →